Lyell Agrees $80 Million Placement Ahead of CAR T Pivotal Data

Previously missed November 4 primary disclosure: Lyell agreed to sell about $80 million of common stock in a private placement to fund pivotal development of dual-target CD19/CD20 CAR T ronde-cel and its GCC CAR…




